SEARCH

SEARCH BY CITATION

References

  • 1
    Hay SI, Guerra CA, Gething PW et al. A world malaria map: Plasmodium falciparum endemicity in 2007. PLoS Med 2009; 6: e1000048.
  • 2
    Hay SI, Okiro EA, Gething PW et al. Estimating the global clinical burden of Plasmodium falciparum malaria in 2007. PLoS Med 2010; 7: e1000290.
  • 3
    Hay SI, Guerra CA, Tatem AJ, Noor AM, Snow RW. The global distribution and population at risk of malaria: past, present, and future. Lancet Infect Dis 2004; 4: 327336.
  • 4
    Gosling RD, Drakeley CJ, Mwita A, Chandramohan D. Presumptive treatment of fever cases as malaria: help or hindrance for malaria control? Malar J 2008; 7: 132.
  • 5
    Bhattarai A, Ali AS, Kachur SP et al. Impact of artemisinin-based combination therapy and insecticide-treated nets on malaria burden in Zanzibar. PLoS Med 2007; 4: e309.
  • 6
    Chizema-Kawesha E, Miller JM, Steketee RW et al. Scaling up malaria control in Zambia: progress and impact 2005–2008. Am J Trop Med Hyg 2010; 83: 480488.
  • 7
    Griffin JT, Hollingsworth TD, Okell LC et al. Reducing Plasmodium falciparum malaria transmission in Africa: a model-based evaluation of intervention strategies. PLoS Med 2010; 7: e2979.
  • 8
    Bousema T, Drakeley C. Epidemiology and infectivity of Plasmodium falciparum and Plasmodium vivax gametocytes in relation to malaria control and elimination. Clin Microbiol Rev 2011; 24: 377410.
  • 9
    Mboera LE, Magesa SM. The rise and fall of malarial sporozoite rates in Anopheles gambiae s.l. and An. funestus in north-eastern Tanzania, between 1934 and 1999. Ann Trop Med Parasitol 2001; 95: 325330.
  • 10
    Barnes KI, Chanda P, Ab Barnabas G. Impact of the large-scale deployment of artemether/lumefantrine on the malaria disease burden in Africa: case studies of South Africa, Zambia and Ethiopia. Malar J 2009; 8 (suppl 1): S8.
  • 11
    Barnes KI, Durrheim DN, Little F et al. Effect of artemether–lumefantrine policy and improved vector control on malaria burden in KwaZulu-Natal, South Africa. PLoS Med 2005; 2: e330.
  • 12
    Nosten F, van Vugt M, Price R et al. Effects of artesunate–mefloquine combination on incidence of Plasmodium falciparum malaria and mefloquine resistance in western Thailand: a prospective study. Lancet 2000; 356: 297302.
  • 13
    Reyburn H, Mbatia R, Drakeley C et al. Overdiagnosis of malaria in patients with severe febrile illness in Tanzania: a prospective study. BMJ 2004; 329: 1212 Epub 2004 November.
  • 14
    Lubell Y, Reyburn H, Mbakilwa H et al. The impact of response to the results of diagnostic tests for malaria: cost-benefit analysis. BMJ 2008; 336: 202205.
  • 15
    Kaneko A, Taleo G, Kalkoa M, Yamar S, Kobayakawa T, Bjorkman A. Malaria eradication on islands. Lancet 2000; 356: 15601564.
  • 16
    Song J, Socheat D, Tan B et al. Rapid and effective malaria control in Cambodia through mass administration of artemisinin–piperaquine. Malar J 2010; 9: 57.
  • 17
    Von Seidlein L, Walraven G, Milligan PJ et al. The effect of mass administration of sulfadoxine–pyrimethamine combined with artesunate on malaria incidence: a double-blind, community-randomized, placebo-controlled trial in The Gambia. Trans R Soc Trop Med Hyg 2003; 97: 217225.
  • 18
    Malisa AL, Pearce RJ, Abdulla S et al. Drug coverage in treatment of malaria and the consequences for resistance evolution—evidence from the use of sulphadoxine/pyrimethamine. Malar J 2010; 9: 190.
  • 19
    Stepniewska K, White NJ. Pharmacokinetic determinants of the window of selection for antimalarial drug resistance. Antimicrob Agents Chemother 2008; 52: 15891596.
  • 20
    White NJ. The treatment of malaria. N Engl J Med 1996; 335: 800806.
  • 21
    Deen JL, von Seidlein L, Pinder M, Walraven GE, Greenwood BM. The safety of the combination artesunate and pyrimethamine–sulfadoxine given during pregnancy. Trans R Soc Trop Med Hyg 2001; 95: 424428.
  • 22
    Kaneko A. A community-directed strategy for sustainable malaria elimination on islands: short-term MDA integrated with ITNs and robust surveillance. Acta Trop 2010; 114: 177183.
  • 23
    Bejon P, Warimwe G, Mackintosh CL et al. Analysis of immunity to febrile malaria in children that distinguishes immunity from lack of exposure. Infect Immun 2009; 77: 19171923.
  • 24
    Bousema T, Drakeley C, Gesase S et al. Identification of hot spots of malaria transmission for targeted malaria control. J Infect Dis 2010; 201: 17641774.
  • 25
    Mwangi TW, Fegan G, Williams TN, Kinyanjui SM, Snow RW, Marsh K. Evidence for over-dispersion in the distribution of clinical malaria episodes in children. PLoS ONE 2008; 3: e2196.
  • 26
    Alonso PL, Djimde A, Kremsner P et al. A research agenda for malaria eradication: drugs. PLoS Med 2011; 8: e1000402.
  • 27
    Hill DR, Baird JK, Parise ME, Lewis LS, Ryan ET, Magill AJ. Primaquine: report from CDC expert meeting on malaria chemoprophylaxis I. Am J Trop Med Hyg 2006; 75: 402415.
  • 28
    Meremikwu MM, Omari AA, Garner P. Chemoprophylaxis and intermittent treatment for preventing malaria in children. Cochrane Database Syst Rev 2005: CD003756.
  • 29
    Cairns M, Carneiro I, Milligan P et al. Duration of protection against malaria and anaemia provided by intermittent preventive treatment in infants in Navrongo, Ghana. PLoS ONE 2008; 3: e2227.
  • 30
    Cairns M, Gosling R, Carneiro I et al. Duration of protection against clinical malaria provided by three regimens of intermittent preventive treatment in Tanzanian infants. PLoS ONE 2010; 5: e9467.
  • 31
    Shekalaghe S, Drakeley C, Gosling R et al. Primaquine clears submicroscopic Plasmodium falciparum gametocytes that persist after treatment with sulphadoxine–pyrimethamine and artesunate. PLoS ONE 2007; 2: e1023.
  • 32
    Mens PF, Sawa P, van Amsterdam SM et al. A randomized trial to monitor the efficacy and effectiveness by QT-NASBA of artemether–lumefantrine versus dihydroartemisinin–piperaquine for treatment and transmission control of uncomplicated Plasmodium falciparum malaria in western Kenya. Malar J 2008; 7: 237.
  • 33
    Gosling RD, Gesase S, Mosha JF et al. Protective efficacy and safety of three antimalarial regimens for intermittent preventive treatment for malaria in infants: a randomised, double-blind, placebo-controlled trial. Lancet 2009; 374: 15211532.
  • 34
    Odhiambo FO, Hamel MJ, Williamson J et al. Intermittent preventive treatment in infants for the prevention of malaria in rural Western kenya: a randomized, double-blind placebo-controlled trial. PLoS ONE 2010; 5: e10016.
  • 35
    Konate AT, Yaro JB, Ouedraogo AZ et al. Intermittent preventive treatment of malaria provides substantial protection against malaria in children already protected by an insecticide-treated bednet in Burkina Faso: a randomised, double-blind, placebo-controlled trial. PLoS Med 2011; 8: e1000408.
  • 36
    Dicko A, Diallo AI, Tembine I et al. Intermittent preventive treatment of malaria provides substantial protection against malaria in children already protected by an insecticide-treated bednet in Mali: a randomised, double-blind, placebo-controlled trial. PLoS Med 2011; 8: e1000407.
  • 37
    Nankabirwa J, Cundill B, Clarke S et al. Efficacy, safety, and tolerability of three regimens for prevention of malaria: a randomized, placebo-controlled trial in Ugandan schoolchildren. PLoS ONE 2010; 5: e13438.
  • 38
    Cisse B, Cairns M, Faye E et al. Randomized trial of piperaquine with sulfadoxine–pyrimethamine or dihydroartemisinin for malaria intermittent preventive treatment in children. PLoS ONE 2009; 4: e7164.
  • 39
    Bojang K, Akor F, Bittaye O et al. A randomised trial to compare the safety, tolerability and efficacy of three drug combinations for intermittent preventive treatment in children. PLoS ONE 2010; 5: e11225.
  • 40
    Okell LC, Drakeley CJ, Bousema T, Whitty CJ, Ghani AC. Modelling the impact of artemisinin combination therapy and long-acting treatments on malaria transmission intensity. PLoS Med 2008; 5: e226; discussion e226.
  • 41
    Okell LC, Drakeley CJ, Ghani AC, Bousema T, Sutherland CJ. Reduction of transmission from malaria patients by artemisinin combination therapies: a pooled analysis of six randomized trials. Malar J 2008; 7: 125.
  • 42
    Tediosi F, Maire N, Smith T et al. An approach to model the costs and effects of case management of Plasmodium falciparum malaria in sub-saharan Africa. Am J Trop Med Hyg 2006; 75: 90103.
  • 43
    Freeman J, Laserson KF, Petralanda I, Spielman A. Effect of chemotherapy on malaria transmission among Yanomami Amerindians: simulated consequences of placebo treatment. Am J Trop Med Hyg 1999; 60: 774780.
  • 44
    Lawpoolsri S, Klein EY, Singhasivanon P et al. Optimally timing primaquine treatment to reduce Plasmodium falciparum transmission in low endemicity Thai–Myanmar border populations. Malar J 2009; 8: 159.
  • 45
    Okell LC, Griffin JT, Kleinschmidt I et al. The potential contribution of mass treatment to the control of Plasmodium falciparum malaria. PLoS ONE 2011; 6: e20179.
  • 46
    Gu W, Killeen GF, Mbogo CM, Regens JL, Githure JI, Beier JC. An individual-based model of Plasmodium falciparum malaria transmission on the coast of Kenya. Trans R Soc Trop Med Hyg 2003; 97: 4350.
  • 47
    White LJ, Maude RJ, Pongtavornpinyo W et al. The role of simple mathematical models in malaria elimination strategy design. Malar J 2009; 8: 212.
  • 48
    Maude RJ, Pontavornpinyo W, Saralamba S et al. The last man standing is the most resistant: eliminating artemisinin-resistant malaria in Cambodia. Malar J 2009; 8: 31.
  • 49
    Ishikawa H, Kaneko A. Computer simulation of a malaria control trial in Vanuatu using a mathematical model with variable vectorial capacity. Jpn J Trop Med Hyg 1996; 24: 1119.
  • 50
    Aguas R, Lourenco JM, Gomes MG, White LJ. The impact of IPTi and IPTc interventions on malaria clinical burden—in silico perspectives. PLoS ONE 2009; 4: e6627.